UNSPSC 51432805: Lisinopril

This classification denotes an ace inhibitor with the molecular formula C21H31N3O5.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E7199S1YWR, chemically known as l-proline, 1-(n(sup 2)-(1-carboxy-3-phenylpropyl)-l-lysyl)-, dihydrate, (s)- but generally known as lisinopril, which bears US NIH Compound Identifier 5362118. European Medicines Agency schedules Lisinopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08533MIG.

UNSPSC 51432805 Lisinopril (Commodity) covers pharmaceuticals supplied to state and local government health and emergency response agencies, though recent solicitations show broader purchasing of advanced life support medications and generic pharmaceuticals rather than lisinopril specifically. State and local governments acquire these drugs through direct vendor procurement tied to emergency medical services, pharmacy benefit programs, and institutional health systems, with supply contracts typically requiring FDA compliance, cGMP certification, minimum shelf-life guarantees, and delivery within days to weeks of order. Issuing bodies span city emergency services departments (Tampa Fire Rescue), state health commissions managing pharmacy benefits (Texas HHS), and multistate cooperative purchasing alliances (MMCAP). The City of Tampa's Purchasing Department and the Minnesota Multistate Cooperative Purchasing Alliance are active repeat participants, signaling that cooperative and regional purchasing frameworks are common vehicles for pharmaceutical procurement at this tier.

Recent activity concentrates in Florida and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, due April 8, 2026, for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Minnesota Department of Administration, administering MMCAP, posted an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with contract terms beginning July 1, 2026, and evaluations weighted heavily on price competitiveness (75 percent). Texas HHS issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs, signaling exploratory state-level interest in alternative supply-chain models outside traditional pharmacy benefit manager arrangements. All recent opportunities require vendors to maintain comprehensive product liability and compliance documentation.